Joana Carvalho, PhD, managing science editor —

Note: This story was updated Aug. 6, 2020, to note that ketoconazole is approved to treat Cushing’s in Europe and is used off-label for the same indication in the U.S. In cases where surgery is temporarily unavailable for Cushing’s syndrome patients due to the COVID-19 pandemic, a…

Estrogen receptor alpha — one of the two main types of protein receptors activated by the female sex hormone estrogen — likely is involved in the development of Cushing’s syndrome during pregnancy. The study with that finding, “Estrogen receptor α plays an important role…

The last patient has completed the last study visit in the withdrawal phase of the Phase 3 LOGICS clinical trial that is investigating the safety and effectiveness of Recorlev (levoketoconazole) in patients with endogenous Cushing’s syndrome. The announcement by Strongbridge Biopharma, the therapy’s developer, says that LOGICS…

Genetic variations in the glucocorticoid receptor may explain why some patients with Cushing’s syndrome lose muscle strength, a study suggests. The study, “Glucocorticoid receptor polymorphisms influence muscle strength in Cushing’s syndrome,” was published in The Journal of Clinical Endocrinology & Metabolism. Cushing’s syndrome is caused…

The oral investigational treatment Recorlev (levoketoconazole) leads to sustained improvements in the control of cortisol among patients with endogenous Cushing’s syndrome, a Phase 3 trial shows. The trial’s findings were reported in the study “Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing’s…

Cushing’s syndrome should be suspected in children and adolescents with evident growth delays, and signs of rapid weight gain, depression, anxiety, and hyperandrogenism, a study finds. While brain surgery to remove a tumor lessens the symptoms of Cushing’s, many children and adolescents end up with…

In real-life clinical practice, Novartis‘ Signifor (pasireotide) completely or nearly normalizes the levels of cortisol in the urine of patients with mild to moderate Cushing’s disease, a study says. The study, “The medical treatment with pasireotide in Cushing’s disease: an Italian multicentre experience based on ‘real-world…

Strongbridge Biopharma is preparing the submission of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking the approval of Recorlev (levoketoconazole) for the treatment of patients with endogenous Cushing’s syndrome. According to recent statements from the company, the…

Strongbridge Biopharma’s Recorlev (levoketoconazole) alleviates clinical signs and symptoms of Cushing’s syndrome that may cause discomfort and distress to patients, a Phase 3 trial shows. The trial’s findings were presented in a poster titled, “Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome: Improvements…

Strongbridge Biopharma‘s Recorlev (levoketoconazole) continues to show clinically meaningful improvements in the control of cortisol among patients with endogenous Cushing’s syndrome, a Phase 3 clinical trial shows. Cushing’s syndrome is caused by the excessive production of the hormone cortisol by the adrenal glands, which sit atop…